JP2023501627A5 - - Google Patents
Info
- Publication number
- JP2023501627A5 JP2023501627A5 JP2022527859A JP2022527859A JP2023501627A5 JP 2023501627 A5 JP2023501627 A5 JP 2023501627A5 JP 2022527859 A JP2022527859 A JP 2022527859A JP 2022527859 A JP2022527859 A JP 2022527859A JP 2023501627 A5 JP2023501627 A5 JP 2023501627A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- fluoro
- aml
- week
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962934923P | 2019-11-13 | 2019-11-13 | |
| US62/934,923 | 2019-11-13 | ||
| PCT/JP2020/042410 WO2021095840A1 (en) | 2019-11-13 | 2020-11-13 | METHODS OF TREATING LSD1-RELATED DISEASES and Disorders WITH LSD1 INHIBITORS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023501627A JP2023501627A (ja) | 2023-01-18 |
| JP2023501627A5 true JP2023501627A5 (https=) | 2023-11-13 |
| JP7492002B2 JP7492002B2 (ja) | 2024-05-28 |
Family
ID=75912767
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022527859A Active JP7492002B2 (ja) | 2019-11-13 | 2020-11-13 | Ｌｓｄ１阻害剤によりｌｓｄ１関連疾患及び障害を治療する方法 |
| JP2022519478A Active JP7379680B2 (ja) | 2019-11-13 | 2020-11-13 | テルフェニル化合物の新規な塩 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022519478A Active JP7379680B2 (ja) | 2019-11-13 | 2020-11-13 | テルフェニル化合物の新規な塩 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US12419858B2 (https=) |
| EP (2) | EP4058151B1 (https=) |
| JP (2) | JP7492002B2 (https=) |
| KR (2) | KR102825246B1 (https=) |
| CN (2) | CN114828844A (https=) |
| AU (2) | AU2020382379B2 (https=) |
| BR (2) | BR112022009221A2 (https=) |
| CA (2) | CA3157404A1 (https=) |
| DK (1) | DK4058151T3 (https=) |
| ES (1) | ES3034158T3 (https=) |
| FI (1) | FI4058151T3 (https=) |
| HU (1) | HUE072206T2 (https=) |
| MX (2) | MX2022005811A (https=) |
| PH (2) | PH12022551169A1 (https=) |
| PL (1) | PL4058151T3 (https=) |
| PT (1) | PT4058151T (https=) |
| TW (2) | TWI874489B (https=) |
| WO (2) | WO2021095835A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018276611B2 (en) | 2017-05-31 | 2022-01-06 | Taiho Pharmaceutical Co., Ltd. | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 |
| WO2021095835A1 (en) | 2019-11-13 | 2021-05-20 | Taiho Pharmaceutical Co., Ltd. | Novel salt of terphenyl compound |
| US20250073232A1 (en) | 2021-04-08 | 2025-03-06 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors for treating myeloid cancers |
| EP4337638A1 (en) * | 2021-05-11 | 2024-03-20 | Astex Pharmaceuticals, Inc. | Solid forms of salts of 4-[5-[(3s)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-ethylpropyl)phenyl]phenyl]-2-fluoro-benzonitrile |
| US20250049757A1 (en) * | 2021-09-30 | 2025-02-13 | Taiho Pharmaceutical Co. Ltd. | Combinatory therapy for cancer using biphenyl compound and immune checkpoint molecule regulator |
| JP7788550B2 (ja) * | 2021-10-26 | 2025-12-18 | 大鵬薬品工業株式会社 | ターフェニル化合物の安息香酸塩の製造方法 |
| US20250295660A1 (en) | 2022-05-09 | 2025-09-25 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
| EP4522136A1 (en) | 2022-05-09 | 2025-03-19 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
| WO2024229073A1 (en) * | 2023-05-02 | 2024-11-07 | Otsuka Pharmaceutical Co., Ltd. | Response-based dosing for treating cancer with a hypomethylating agent and cedazuridine |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8801518D0 (sv) * | 1988-04-22 | 1988-04-22 | Astra Pharma Prod | A novel process |
| US6225049B1 (en) | 1992-06-17 | 2001-05-01 | The United States Of America As Represented By The Department Of Health And Human Services | Human insulinoma-associated cDNA |
| CA2469649C (en) | 2001-12-13 | 2011-05-03 | Natrogen Therapeutics, Inc. | Derivatives of isoindigo, indigo and indirubin and use in treating cancer |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| EP1792622A1 (en) | 2005-11-11 | 2007-06-06 | GPC Biotech AG | Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and EGFR inhibitors or pyrimidine analogues |
| JP2011530511A (ja) | 2008-08-05 | 2011-12-22 | メルク・シャープ・エンド・ドーム・コーポレイション | 治療用化合物 |
| EP2350317A4 (en) | 2008-10-20 | 2012-06-27 | Univ Colorado Regents | BIOLOGICAL MARKERS FOR PREDICTING THE ANTICIPATE RESPONSE TO INSULINARY GROWTH FACTOR 1 RECEPTOR KINASE INHIBITORS |
| US8367679B2 (en) | 2008-12-09 | 2013-02-05 | Merck Sharp & Dohme Corp. | Biaryl carboxamides |
| EP2419177A1 (en) | 2009-04-17 | 2012-02-22 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| BR112012027062B8 (pt) | 2010-04-20 | 2021-05-25 | Fond Ieo | composto, processo para a preparação de um composto e usos do mesmo |
| BR112013002164B1 (pt) | 2010-07-29 | 2021-11-09 | Oryzon Genomics S.A. | Inibidores de desmetilase à base de arilciclopropilamina de lsd1, seus usos, e composição farmacêutica |
| WO2012157647A1 (ja) | 2011-05-16 | 2012-11-22 | 大鵬薬品工業株式会社 | 胃癌患者に対するテガフール・ギメラシル・オテラシルカリウム配合剤及びｅｇｆｒ阻害剤からなる化学療法の選択方法 |
| EP2768805B1 (en) | 2011-10-20 | 2020-03-25 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| CN104411316B (zh) * | 2012-05-09 | 2018-05-01 | 坎泰克斯制药股份有限公司 | 骨髓抑制的治疗 |
| US9834521B2 (en) | 2013-03-15 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Choline kinase inhibitors |
| ES2734209T3 (es) | 2013-08-06 | 2019-12-04 | Imago Biosciences Inc | Inhibidores de KDM1A para el tratamiento de enfermedades |
| US9266907B2 (en) | 2013-09-05 | 2016-02-23 | King Abdullah University Of Science And Technology | Tunable rare-earth fcu-metal-organic frameworks |
| CA3161836A1 (en) | 2013-12-11 | 2015-06-18 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
| CN106061969B (zh) | 2014-01-06 | 2019-10-29 | 阿尔戈么迪克斯有限公司 | Trpa1调节剂 |
| KR102400920B1 (ko) | 2014-05-01 | 2022-05-20 | 셀젠 콴티셀 리서치, 인크. | 리신 특이적 데메틸라제-1의 억제제 |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| CA2958704A1 (en) | 2014-08-25 | 2016-03-03 | University Of Canberra | Compositions for modulating cancer stem cells and uses therefor |
| AU2015311805B2 (en) | 2014-09-05 | 2020-04-02 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
| EP3285809B1 (en) | 2015-04-20 | 2019-09-11 | eFFECTOR Therapeutics, Inc. | Inhibitors of immune checkpoint modulators for use in treating cancer and infections |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| EP3381896B1 (en) * | 2015-11-27 | 2023-01-18 | Taiho Pharmaceutical Co., Ltd. | Biphenyl compound or salt thereof |
| WO2018136961A1 (en) | 2017-01-23 | 2018-07-26 | Syros Pharmaceuticals Inc. | METHODS OF TREATING PATIENTS WITH A RETINOIC ACID RECEPTOR-α AGONIST AND AN ANTI-CD38 ANTIBODY |
| TWI770925B (zh) * | 2017-05-26 | 2022-07-11 | 日商大鵬藥品工業股份有限公司 | 使用有新穎聯苯化合物之抗腫瘤效果增強劑 |
| KR102361918B1 (ko) | 2017-05-26 | 2022-02-14 | 다이호야쿠힌고교 가부시키가이샤 | 신규 비페닐 화합물 또는 그의 염 |
| AU2018276611B2 (en) * | 2017-05-31 | 2022-01-06 | Taiho Pharmaceutical Co., Ltd. | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 |
| KR20200020899A (ko) | 2017-06-30 | 2020-02-26 | 셀진 코포레이션 | 2-(4-클로로페닐)-n-((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-5-일)메틸)-2,2-디플루오로아세트아미드의 조성물 및 사용 방법 |
| WO2019075327A1 (en) | 2017-10-12 | 2019-04-18 | Dana-Farber Cancer Institute, Inc. | TREATMENT OF MERKEL CELL CARCINOMA |
| WO2019083971A1 (en) | 2017-10-23 | 2019-05-02 | Children's Medical Center Corporation | METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY |
| AU2018377852B2 (en) | 2017-11-29 | 2022-03-24 | Epiaxis Therapeutics Pty Ltd | Enhancing T-cell function and treating a T-cell dysfunctional disorder with a combination of an LSD inhibitor and a PD1 binding antagonist |
| KR20200105662A (ko) | 2018-01-02 | 2020-09-08 | 셀진 코포레이션 | 2-(4-클로로페닐)-n-((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-5-일)메틸)-2,2-디플루오로아세트아미드의 동위 이성질체 |
| IL289453B2 (en) | 2019-07-17 | 2026-03-01 | Summit Oxford Ltd | Process for preparing ridinilazole and its crystalline forms |
| WO2021095835A1 (en) | 2019-11-13 | 2021-05-20 | Taiho Pharmaceutical Co., Ltd. | Novel salt of terphenyl compound |
| EP4114398A1 (en) | 2020-03-06 | 2023-01-11 | Celgene Quanticel Research, Inc. | Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc |
-
2020
- 2020-11-13 WO PCT/JP2020/042383 patent/WO2021095835A1/en not_active Ceased
- 2020-11-13 PT PT208862615T patent/PT4058151T/pt unknown
- 2020-11-13 ES ES20886261T patent/ES3034158T3/es active Active
- 2020-11-13 BR BR112022009221A patent/BR112022009221A2/pt unknown
- 2020-11-13 TW TW109139799A patent/TWI874489B/zh active
- 2020-11-13 HU HUE20886261A patent/HUE072206T2/hu unknown
- 2020-11-13 DK DK20886261.5T patent/DK4058151T3/da active
- 2020-11-13 KR KR1020227019781A patent/KR102825246B1/ko active Active
- 2020-11-13 TW TW109139813A patent/TWI874490B/zh active
- 2020-11-13 PL PL20886261.5T patent/PL4058151T3/pl unknown
- 2020-11-13 EP EP20886261.5A patent/EP4058151B1/en active Active
- 2020-11-13 JP JP2022527859A patent/JP7492002B2/ja active Active
- 2020-11-13 JP JP2022519478A patent/JP7379680B2/ja active Active
- 2020-11-13 PH PH1/2022/551169A patent/PH12022551169A1/en unknown
- 2020-11-13 WO PCT/JP2020/042410 patent/WO2021095840A1/en not_active Ceased
- 2020-11-13 MX MX2022005811A patent/MX2022005811A/es unknown
- 2020-11-13 AU AU2020382379A patent/AU2020382379B2/en active Active
- 2020-11-13 PH PH1/2022/551137A patent/PH12022551137A1/en unknown
- 2020-11-13 EP EP20886658.2A patent/EP4058018A4/en active Pending
- 2020-11-13 CA CA3157404A patent/CA3157404A1/en active Pending
- 2020-11-13 AU AU2020382214A patent/AU2020382214B2/en active Active
- 2020-11-13 BR BR112022008020A patent/BR112022008020A2/pt unknown
- 2020-11-13 CA CA3158442A patent/CA3158442A1/en active Pending
- 2020-11-13 US US17/775,795 patent/US12419858B2/en active Active
- 2020-11-13 CN CN202080079021.0A patent/CN114828844A/zh active Pending
- 2020-11-13 KR KR1020227019783A patent/KR20220113390A/ko not_active Ceased
- 2020-11-13 US US17/775,800 patent/US20220387384A1/en active Pending
- 2020-11-13 CN CN202080078991.9A patent/CN114728899B/zh active Active
- 2020-11-13 FI FIEP20886261.5T patent/FI4058151T3/fi active
- 2020-11-13 MX MX2022005812A patent/MX2022005812A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023501627A5 (https=) | ||
| JP2023541430A5 (https=) | ||
| JP2023541432A5 (https=) | ||
| AU2018357775B2 (en) | New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD) | |
| PH12022551169A1 (en) | METHODS OF TREATING LSD1-RELATED DISEASES and Disorders WITH LSD1 INHIBITORS | |
| JP2021527092A5 (https=) | ||
| JP2014515373A5 (https=) | ||
| BR112015010063B1 (pt) | Uso de uma composição compreendendo colchicina, um sal de colchicina ou combinação desses | |
| ITFI20080035A1 (it) | Composizione odontoiatrica per la prevenzione ed il trattamento della stomatite e delle ulcerazoni della mucosa orale | |
| US20150005252A1 (en) | Combination therapy for the treatment of cancer | |
| JP2014515408A5 (https=) | ||
| MY209220A (en) | Dosing regimen for the treatment of pi3k related disorders | |
| JP2024531188A5 (https=) | ||
| JP2018138596A5 (https=) | ||
| RU2007107915A (ru) | Лекарственные средства для лечения хронического респираторного заболевания | |
| EP3765059A1 (en) | Methods of treating or preventing acute respiratory distress syndrome | |
| EP4087555A1 (en) | Methods of using andrographolide, oridonin and isoliquiritigenin and derivatives thereof | |
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| JP2023553253A5 (https=) | ||
| JP2016505050A5 (https=) | ||
| JP7208139B2 (ja) | 双極性障害の予防、軽減又は治療のためのカルバメート化合物の使用 | |
| JP2023520703A5 (https=) | ||
| MX384760B (es) | Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático. | |
| JP2021511352A5 (https=) | ||
| CN115607545B (zh) | 依达拉奉在自闭症谱系障碍治疗中的应用 |